June 30, 2026 10:15 am (IST)
Follow us:
Emerging markets affect Dr Reddy's Laboratories' December quarter performance
Hyderabad, Feb 9 (IBNS) Dr Reddy's Laboratories Ltd announced its consolidated financial results on Tuesday for the quarter ended December 31, 2015, where it posted consolidated revenue of ₹39.7 billion, up 3 per cent from the same period in 2014, largely because the healthy performance in North America Generics (NAG), Europe and India were partially offset by emerging markets, which were impacted by unfavorable macro-economic conditions.
Revenues from the Global Generics segment for the reported quarter was ₹33.6 billion, up 7 per cent from the year-ago quarter, primarily driven by North America, Europe and India.
Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment was ₹5.1 billion in the reported quarter, and declined by 17 per cent from the same quarter a year ago.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
From Mumbai teen to AI trailblazer: Meet 19-year-old Dhravya Shah behind Supermemory's $3 million funding
Mon, Jun 29 2026
Stop exchanging currency! You can use UPI app in Seychelles in future. List of other nations where the app can be used
Mon, Jun 29 2026
Why did Kotak Mahindra Bank stock fall 3% today? CEO Ashok Vaswani's decision explained
Mon, Jun 29 2026
India overtakes Taiwan, South Korea to become world's fifth-largest equity market again
Mon, Jun 29 2026
Best Car Insurance for Cars Driven Less Than 5,000 KM a Year
Sat, Jun 27 2026